Med LifeBSE:M +0.53%90 Net Margin % is 1.15% as of Mar. 2026, which is 26% below its 10-year median of 1.55. GuruFocus rates BSE:M with a GF Score™ of 90/100 and a GF Value™ of lei7.82 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Med Life ranks worse than 64.22% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Med Life's Net Income for the
three
months ended in Mar. 2026 was lei10 Mil. Med Life's Revenue for the
three
months ended in Mar. 2026 was lei853 Mil. Therefore, Med Life's net margin for the quarter that ended in Mar. 2026 was 1.15%.
The historical rank and industry rank for Med Life's Net Margin % or its related term are showing as below:
BSE:M'
s Net Margin % Range Over the Past 10 Years
Min: -1.02 Med: 1.55 Max: 7.19
Current: 0.05
BSE:M's Net Margin % is ranked worse than 64.22% of 668
companies
in the Healthcare Providers & Services industry
Industry Median: 2.885
vs BSE:M: 0.05
Med Life (BSE:M) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Med Life Net Margin % Related Terms
Med Life Net Margin % Historical Data
* Premium members only.
The historical data trend for Med Life's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Med Life's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Med Life Net Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Med Life's Net Margin % distribution charts can be found below:
* The bar in red indicates where Med Life's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Med Life (BSE:M) has a Net Margin % of 1.15% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Med Life and its competitors. This is 26% below median its historical median of 1.55. According to the industry distribution chart, Med Life ranks #429 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 64.2%.
Is Med Life's Net Margin % too high?
Med Life's current Net Margin % of 1.15% is 26% below median its 10-year median of 1.55. The Healthcare Providers & Services industry median Net Margin % is 2.89. Med Life's value of 1.15% is 60.1% below this industry median. Based on the distribution chart, Med Life ranks #429 out of 668 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Med Life has a GF Score™ of 90/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Med Life's Net Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Med Life ranks #429 out of 668 companies for Net Margin %. This places Med Life in the lower half of its industry. The industry median Net Margin % is 2.89. Med Life's value of 1.15% is 60.1% below this benchmark. While the company's 10-year median is 1.55 vs. the industry median of 2.89, Med Life has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Healthcare Providers & Services company?
The median Net Margin % among Healthcare Providers & Services companies is 2.89, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Med Life's current Net Margin % of 1.15% is 60.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Med Life and its competitors. For the Healthcare Providers & Services industry, the median Net Margin % is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Med Life's current Net Margin % is 1.15%, which is 26% below median its own 10-year median of 1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Med Life stock overvalued right now?
Based on GuruFocus' analysis, Med Life (BSE:M) is currently considered Significantly Overvalued. The stock's GF Value™ is lei7.82, compared to a current price of lei11.36 — trading 45.3% above its estimated fair value. The current Net Margin % is 1.15%, which is 26% below median its 10-year median of 1.55 and 60.1% below the Healthcare Providers & Services industry median of 2.89. Med Life's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Med Life (BSE:M), the current Net Margin % is 1.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Med Life (BSE:M) Overvalued in 2026?
Based on GuruFocus' analysis, Med Life stock appears to be overvalued.
The current stock price of lei11.36 is trading 45.3% above its estimated GF Value™ of lei7.82.
GuruFocus considers Med Life to be Significantly Overvalued.
Key valuation signals for BSE:M:
Net Margin %: 1.15% (26% below median its 10-year median of 1.55)
GF Value™: lei7.82 vs. price of lei11.36 (45.3% above fair value)
Industry Position: 60.1% below the Healthcare Providers & Services median (#429 of 668)
No single metric tells the full story. See the BSE:M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Med Life SA is a healthcare provider in Romania. The Company's activity resides in the performance of healthcare services activities through medical centres with national coverage. It is engaged in the provision of rendering of medical services, rental of medical facilities and acquisition of materials and commodities. The company provides medical service through Hyper clinics in Arad, Bucharest, Braila, Brasov, Cluj, Constanta, Craiova, Galati, Iasi, Oradea, Ploiesti, Sibiu and Timisoara; Clinics, hospitals located in Bucharest, Arad, Sibiu, Brasov, Cluj and Ploiesti, Laboratories, Pharmacies and Dental Clinics.
90GF Score
Get the complete analysis for BSE:M
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSE:M has been successfully added to your 
